Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Profit After Tax (2016 - 2025)

Fate Therapeutics' Profit After Tax history spans 14 years, with the latest figure at -$32.4 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 37.92% year-over-year to -$32.4 million; the TTM value through Dec 2025 reached -$136.3 million, up 26.82%, while the annual FY2025 figure was -$136.3 million, 26.82% up from the prior year.
  • Profit After Tax reached -$32.4 million in Q4 2025 per FATE's latest filing, roughly flat from -$32.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$18.9 million in Q1 2023 to a low of -$83.6 million in Q3 2022.
  • Average Profit After Tax over 5 years is -$48.9 million, with a median of -$46.4 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: surged 71.26% in 2023, then crashed 154.25% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$68.7 million in 2021, then grew by 17.9% to -$56.4 million in 2022, then increased by 21.72% to -$44.1 million in 2023, then decreased by 18.2% to -$52.2 million in 2024, then skyrocketed by 37.92% to -$32.4 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Profit After Tax are -$32.4 million (Q4 2025), -$32.2 million (Q3 2025), and -$34.1 million (Q2 2025).